Michael R. Liebowitz, Jason Careri, Kyra Blatt et Ann Draine, « Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder », Depression and Anxiety, vol. 34, no 12, , p. 1164–1172 (ISSN1520-6394, PMID29166552, DOI10.1002/da.22702, lire en ligne, consulté le )
RS McIntyre, J Harrison, H Loft et W Jacobson, « The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials », International Journal of Neuropsychopharmacology, vol. 19, no 10, (ISSN1461-1457, PMID27312740, PMCID5091829, DOI10.1093/ijnp/pyw055, lire en ligne, consulté le )
Marc Kelliny, Paul E Croarkin, Katherine M Moore et William V Bobo, « Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature », Therapeutics and Clinical Risk Management, vol. 11, , p. 1193–1212 (ISSN1176-6336, PMID26316764, PMCID4542474, DOI10.2147/TCRM.S55313, lire en ligne, consulté le )
Michael R. Liebowitz, Jason Careri, Kyra Blatt et Ann Draine, « Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder », Depression and Anxiety, vol. 34, no 12, , p. 1164–1172 (ISSN1520-6394, PMID29166552, DOI10.1002/da.22702, lire en ligne, consulté le )
RS McIntyre, J Harrison, H Loft et W Jacobson, « The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials », International Journal of Neuropsychopharmacology, vol. 19, no 10, (ISSN1461-1457, PMID27312740, PMCID5091829, DOI10.1093/ijnp/pyw055, lire en ligne, consulté le )
Marc Kelliny, Paul E Croarkin, Katherine M Moore et William V Bobo, « Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature », Therapeutics and Clinical Risk Management, vol. 11, , p. 1193–1212 (ISSN1176-6336, PMID26316764, PMCID4542474, DOI10.2147/TCRM.S55313, lire en ligne, consulté le )
Jancin B. Lu AA21004 Looks Promising for Depression. Clinical Psychiatry News. Décembre 2009. 37(12):24-25. PMID19909980
(en) Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. « A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major dépressive disorder » The International Journal of Neuropsychopharmacology. Juillet 2011 1–12. PMID21767441
(en) Katona C, Hansen T, Olsen Ck. « A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major dépressive disorder » International clinical psychopharmacology. Mai 2012 (préparution) PMID22572889
(en) Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. « A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of lu aa21004 in adults with major depressive disorder » The Journal of clinical psychiatry, août 2012 (préparution) PMID22901346
(en) Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. « A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder » The international journal of neuropsychopharmacology. 11 septembre 2012 (préparution) PMID22963932
(en) Mahableshwarkar AR, Jacobsen PL, Chen Y. À « Randomized, Double-Blind Trial of 2,5 mg and 5 mg Vortioxetine (Lu AA21004) Versus Placebo for 8 Weeks in Adults With Major Depressive Disorder » Current medical research and opinion. 20 décembre 2012 (préparution) PMID23252878
Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. European neuropsychopharmacology. 13 août 2012 (préparution) PMID22898365
Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. European neuropsychopharmacology. 14 août 2012 (préparution) PMID22901736
Michael R. Liebowitz, Jason Careri, Kyra Blatt et Ann Draine, « Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder », Depression and Anxiety, vol. 34, no 12, , p. 1164–1172 (ISSN1520-6394, PMID29166552, DOI10.1002/da.22702, lire en ligne, consulté le )
Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacology, biochemistry, and behavior. 1er février 2013 (préparution) PMID23380522
RS McIntyre, J Harrison, H Loft et W Jacobson, « The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials », International Journal of Neuropsychopharmacology, vol. 19, no 10, (ISSN1461-1457, PMID27312740, PMCID5091829, DOI10.1093/ijnp/pyw055, lire en ligne, consulté le )
Marc Kelliny, Paul E Croarkin, Katherine M Moore et William V Bobo, « Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature », Therapeutics and Clinical Risk Management, vol. 11, , p. 1193–1212 (ISSN1176-6336, PMID26316764, PMCID4542474, DOI10.2147/TCRM.S55313, lire en ligne, consulté le )
Bang-Andersen B, Ruhland T, Jørgensen M, et al.. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry. Mai 2011. 54(9)3206–21. PMID21486038
